PAZ320 is a chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose, as it blocks the action of carbohydrate-hydrolyzing enzymes.
The trial will comprise adults aged 18-75 years with Type 2 diabetes, either on oral agents or insulin with a BMI of 25-35 kg/m2 and with A1c of less than 9.0%.
Boston Therapeutics CEO Sushela Chaidarun said PAZ320 has shown significant reduction of post-meal elevation of glucose in preclinical models.